Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$4.74 USD
+0.09 (1.94%)
Updated May 3, 2024 04:00 PM ET
After-Market: $4.74 0.00 (0.00%) 7:44 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Inozyme Pharma, Inc. [INZY]
Reports for Purchase
Showing records 1 - 20 ( 68 total )
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Topline Results For INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency Expected Early April
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
INZY Full of ENERGY, and with Adult Topline Data Around the Corner
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Topline Data From Phase 1/2 Trials in Adults With ENPP1 Deficiency and ABCC6 Deficiency Expected 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim Data From Phase 1/2 Trial in Adults With ENPP1 Deficiency
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life SciencesThis report contains brief updates on the following: INZY, IKNA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Preserving Pyrophosphate with ENPP1 and ABCC6 Data Around the Corner
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Data Readouts For INZ-701 in Adults With ENPP1 Deficiency and ABCC6 Deficiency Expected in September
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E